Polymorphism of IL-1α, IL-1β and IL-10 in patients with advanced ovarian cancer: Results of a prospective study with 147 patients

Braicu, Elena Ioana; Mustea, Alexander; Toliat, Mohammad Reza; Pîrvulescu, Cristina; Könsgen, Dominique; Sun, Pengming; Nürnberg, Peter; Lichtenegger, W.; Sehouli, Jalid

doi:10.1016/j.ygyno.2006.10.014

Cited by 33 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the association of IL‐1A −889C/T polymorphism and cancer risk was not uniform, even conflicting in specific population and various case–control studies. Ioana Braicu et al [29] showed that IL‐1A −889C/T polymorphism does not appear to be risk factor for ovarian cancer; No association was found between prostate cancer risk and IL‐1A −889C/T polymorphisms in Spanish populations [30], these were consistent with the present results. In our study, the −889C/T was not associated with the NPC susceptibility.…”

Section: Discussionsupporting

confidence: 91%

Association of IL‐1 polymorphisms and IL‐1 serum levels with susceptibility to nasopharyngeal carcinoma

Yang

Dai

Zhong

et al. 2010

Molecular Carcinogenesis

View full text Add to dashboard Cite

Previous studies demonstrated that the polymorphism of interleukin-1 (IL-1) produce alterations of the protein expression and may contribute to oncogenetic processes. The aim of this study was to investigate the relationship between IL-1A gene polymorphisms and NPC susceptibility and the influence of on IL-1α serum levels in cases versus controls. To test whether the genetic variants of IL-1A gene modify the risk of nasopharyngeal carcinoma (NPC), we compared the -889C/T and rs3783553 polymorphisms between 248 patients with NPC and 296 healthy controls using polymerase chain reaction-restriction fragment length polymorphism. Serum IL-1α levels were measured by enzyme-linked immunosorbent assay. The rs3783553 (TTCA insertion or deletion) polymorphism of the IL-1A gene was significantly associated with the susceptibility to NPC. The variant homozygote genotype +/+ was associated with a significantly reduced risk of NPC as compared with the wild homozygote -/- genotype, and the serum IL-1α levels were significantly lower in individuals with homozygous +/+ genotypes. No association was found between the -889C/T polymorphisms and risk of NPC, and no statistically significant differences were found between rs3783553 polymorphism and clinical pathology indices. The IL-1A rs3783553 polymorphism might contribute to a risk of developing NPC by affecting the serum IL-1α secretion in the Chinese population.

show abstract

Section: Discussionsupporting

confidence: 91%

Association of IL‐1 polymorphisms and IL‐1 serum levels with susceptibility to nasopharyngeal carcinoma

Yang

Dai

Zhong

et al. 2010

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

“…IL1B encodes IL1beta, a pro-inflammatory cytokine that also has multiple effects on both the immune system and directly on ovarian cancer cells [154]. In another prospective study of 147 advanced ovarian cancer patients, an association between two IL10 promoter polymorphisms and disease-free and overall survival overall survival was observed, possibly due to its relationship with optimal tumor debulking [155]. Lastly, in addition to cytokines, genes encoding other modulators of the immune system have been implicated in disease recurrence and progression.…”

Section: Novel Targets Identified By Analysis Of Genetic Variationmentioning

confidence: 99%

RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer

Knutson

Karyampudi

Lamichhane

et al. 2014

Cancer Metastasis Rev

View full text Add to dashboard Cite

Clinical outcomes, such as recurrence free survival and overall survival, in ovarian cancer are quite variable, independent of common characteristics such as stage, response to therapy and grade. This disparity in outcomes warrants further exploration and therapeutic targeting into the interaction between the tumor and host. One compelling host characteristic that contributes both to the initiation and progression of ovarian cancer is the immune system. Hundreds of studies have confirmed a prominent role for the immune system in modifying the clinical course of the disease. Recent studies also show that anti-tumor immunity is often negated by immune regulatory cells present in the tumor microenvironment. Regulatory immune cells also directly enhance the pathogenesis through the release of various cytokines and chemokines, which together form an integrated pathologic network. Thus, in the future, research into immunotherapy targeting ovarian cancer will probably become increasingly focused on combination approaches that simultaneously augment immunity while preventing local immune suppression. In this article, we summarize important immunological targets that influence ovarian cancer outcome as well as include an update on newer immunotherapeutic strategies.

show abstract

“…The mechanism of rs3783553 polymorphism affecting the risk of ovarian cancer is urgently needed. The results published by Braicu et al [23], regarding the role of IL-10 polymorphism in the pathogenesis of ovarian cancer, revealed the polymorphism of IL-10 promoter gene significantly correlated with the residual tumor mass. This is an infrequent article demonstrated that gene polymorphism was linked with the optimal cytoreductive surgery-the only controllable factor affecting overall survival of ovarian cancer patients.…”

Section: Discussionmentioning

confidence: 94%

“…Results from Frede S's group suggest that IL-1b induced the expression of adrenomedullin mRNA through activation of hypoxia inducible factor 1 and enhanced the hypoxia-induced expression in the human ovarian cancer cell line ''OVCAR-3'' [22]. Though studies had showed that IL-1A-889C/T polymorphism might influences IL-1a expression in cancer, Braicu et al [23] found IL-1A-899C/T polymorphism did not appear to be a risk factor for ovarian cancer. Another research group demonstrated that allele 2 polymorphism of the IL-RN gene is significantly associated with ovarian cancer [13], while presence of the IL-1RN allele 2 was associated with enhanced IL-1b production in vitro [24].…”

Section: Discussionmentioning

confidence: 99%

A polymorphism at miRNA-122-binding site in the IL-1α 3′UTR is associated with risk of epithelial ovarian cancer

et al. 2014

View full text Add to dashboard Cite

We aimed to investigate the association between rs3783553 polymorphism and susceptibility to epithelial ovarian cancer in a Chinese population and discussed the risk factors associated with survival time. In a case-control study, 301 patients diagnosed with epithelial ovarian cancer and 240 healthy controls were genotyped for rs3783553 polymorphism. Survival time of ovarian cancer patients was explored by Kaplan-Meier analysis and Cox proportional hazards modeling. The distributions of genotype and allele frequencies were significantly different between cases and controls. The variant homozygote (ins/ins) was associated with a significantly reduced risk of ovarian cancer. The patients with del/ins polymorphism seemed to be diagnosed "earlier" (FIGO stage I-II) and be more likely to achieve optimal cytoreductive surgery. Advanced FIGO stage (stages III-IV) and non-optimal cytoreductive surgery (residual tumor <1 cm) were poor prognostic factors in the univariate analysis. However, optimal cytoreductive surgery was found to be the only independent significant prognostic factor. This study suggests that rs3783553 polymorphism may be involved in the susceptibility to epithelial ovarian cancer. It may also be related with the tumor stage and the ability to achieve optimal tumor surgery, while the latter predicts the clinical outcomes for patients as the only independent prognostic factor.

show abstract

Polymorphism of IL-1α, IL-1β and IL-10 in patients with advanced ovarian cancer: Results of a prospective study with 147 patients

Cited by 33 publications

References 22 publications

Association of IL‐1 polymorphisms and IL‐1 serum levels with susceptibility to nasopharyngeal carcinoma

Association of IL‐1 polymorphisms and IL‐1 serum levels with susceptibility to nasopharyngeal carcinoma

RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer

A polymorphism at miRNA-122-binding site in the IL-1α 3′UTR is associated with risk of epithelial ovarian cancer

Contact Info

Product

Resources

About